Premier and Octagon Announce Strategic Partnership
A new partnership between Premier Research Group and Octagon Research Solutions will expand the companies' solution sets.
Philadelphia, PA-April 29, 2008-Premier Research Group (www.premier-research.com), the international pharmaceutical services group, and Octagon Research Solutions ( www.octagonresearch.com), a leader in the electronic transformation of clinical R&D in the life sciences industry, today announce the formalization of a partnership agreement to provide a broader solution set.
This new partnership combines Octagon’s expertise in electronic submissions with Premier Research’s extensive clinical expertise across a wide array of therapeutic areas. The partnership enables Premier Research to offer Octagon’s electronic submission capabilities as part of its Regulatory Affairs services and for Octagon to offer Premier’s regulatory development and scientific strategy.
James Ottinger, vice president of global consulting and compliance for Premier Research noted, “Our partnership with Octagon broadens our services by offering Octagon’s proven expertise in the technical aspects of electronic submissions while we continue to focus on our core strengths of regulatory strategy and consulting. We are pleased to be working with an organization that also values our deep commitment to being a ‘solution provider’ for our clients.”
“Premier Research has a solid history of consistent, quality delivery that aligns with our own high standard of operation. We believe that the collaboration will ultimately provide a strong product for our valued customers,” commented Jim Walker, chairman and chief excutive officer, Octagon Research Solutions.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
